← Back to guidelines
Palliative Care4 papers

Mast cell sarcoma

Last edited: 4/15/2026

Overview

Mast cell sarcoma is a rare and aggressive neoplasm characterized by the malignant proliferation of mast cells, often presenting with systemic involvement but occasionally found in isolated, unusual locations such as the brain 1.

Diagnosis

  • Histopathologic confirmation essential using specific stains to identify mast cell immunophenotype and proliferative activity 1.
  • Imaging studies (e.g., MRI) crucial for localization and extent of disease 1.
  • Biopsy required for definitive diagnosis and grading based on morphology and mitotic index 1.
  • Management

  • First-line treatment: Irradiation and intrathecal cytarabine may be considered but showed limited efficacy in the case presented 1.
  • Adjunctive therapy: Combination chemotherapy demonstrated marked transient tumor regression in intracranial cases 1.
  • - Specific regimen not detailed, but polychemotherapy approach suggested 1.

    Special Populations

  • Pediatrics: An isolated case report in an 8-year-old suggests that pediatric patients may respond to aggressive chemotherapy regimens 1.
  • Key Recommendations

  • Histopathologic confirmation with specific stains is essential for diagnosing mast cell sarcoma (Evidence: Moderate 1).
  • Combination chemotherapy should be considered for localized aggressive cases, particularly in unusual locations like the brain, despite transient responses (Evidence: Weak 1).
  • Irradiation and intrathecal cytarabine may be adjunctive but are not sufficient as standalone treatments (Evidence: Expert opinion 1).
  • References

    1 Guenther PP, Huebner A, Sobottka SB, Neumeister V, Weissbach G, Todt H et al.. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. Journal of pediatric hematology/oncology 2001. link

    Original source

    1. [1]
      Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.Guenther PP, Huebner A, Sobottka SB, Neumeister V, Weissbach G, Todt H et al. Journal of pediatric hematology/oncology (2001)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG